canabbis antinode

Reading File
Searching the Web

cannabis anandamide endocannabinoid system

Finding Sources
Finding Sources
Reading File
Reading File
I now have solid textbook content. Here is the full answer:

Cannabis and Anandamide - The Endocannabinoid System

(Interpreting your query as "cannabis and anandamide" - let me know if you meant something else)

What Is Anandamide?

Anandamide (N-arachidonoylethanolamine, AEA) is the brain's own naturally produced, cannabis-like neurotransmitter - sometimes called "the bliss molecule." Along with 2-arachidonoylglycerol (2-AG), it is one of the two primary endocannabinoids - lipid-based signaling molecules that make up the body's endocannabinoid system (ECS).
The ECS was actually discovered because scientists were studying cannabis. Key milestones:
  • 1964: Isolation of THC from cannabis
  • 1988: CB1 cannabinoid receptors identified in the brain
  • 1990: CB1 receptor cloned
  • 1992: Anandamide discovered as the first endogenous brain endocannabinoid
  • 1993: CB2 receptor identified
(Kaplan and Sadock's Synopsis of Psychiatry)

The Endocannabinoid System

The ECS has three main components:
ComponentDetail
CB1 receptorsPrimarily in the CNS (brain); very high density on presynaptic terminals
CB2 receptorsAlso in brain, but mainly in peripheral immune cells
EndocannabinoidsAnandamide (partial agonist) and 2-AG (full agonist) at both receptors
Unlike classic neurotransmitters, endocannabinoids are not stored in vesicles. They are synthesized on-demand from postsynaptic lipid membrane precursors when calcium flows in or when metabotropic receptors are activated (e.g., by acetylcholine or glutamate).
They then travel retrograde - backwards across the synapse - to activate CB1 receptors on the presynaptic neuron and suppress transmitter release. This feedback mechanism can cause transient or long-lasting suppression of neurotransmitter release.
(Katzung's Basic and Clinical Pharmacology, 16th Ed.)

How THC Hijacks the Endocannabinoid System

THC (delta-9-tetrahydrocannabinol) mimics anandamide. It binds CB1 and CB2 receptors as an exogenous agonist and produces effects similar to - but far more potent and prolonged than - anandamide.
  • Anandamide is a partial agonist at CB1/CB2 and is rapidly broken down by the enzyme fatty acid amide hydrolase (FAAH)
  • THC is also a partial agonist but is not degraded by FAAH, so its effects last much longer
  • CBD (cannabidiol) is an isomer of THC but is relatively inactive at CB1 and CB2 - it is non-psychoactive, and its mechanism is not fully understood; it may even be antipsychotic and anxiolytic
(Stahl's Essential Psychopharmacology)

Effects of Cannabis (via CB1 Activation)

In normal doses for low-risk individuals:
  • Sense of well-being, relaxation
  • Friendliness, euphoria
  • Loss of temporal awareness
  • Appetite stimulation
  • Mild analgesia
Higher-potency THC (lower CBD ratio) increases risk of:
  • Hallucinations, delusions
  • Anxiety, memory impairment
  • Precipitation of psychosis in vulnerable individuals
Cannabis has become more potent over time due to selective breeding for higher THC and lower CBD content. One influential European study found that if high-potency cannabis were eliminated, 12% of first-episode psychosis cases across Europe could be prevented - rising to 50% in Amsterdam.

Anandamide as a Target

Because anandamide is degraded by FAAH, FAAH inhibitors have been investigated as therapeutic targets - raising endogenous anandamide levels to produce analgesic, anxiolytic, and anti-inflammatory effects without the psychoactive properties of THC. CBD also indirectly raises anandamide levels by inhibiting FAAH.

Sources:
  • Stahl's Essential Psychopharmacology, Neuroscientific Basis, Cannabis section
  • Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 21 - Endocannabinoids
  • Kaplan and Sadock's Synopsis of Psychiatry, Table 33-5 (cannabinoid timeline)

Canabbis toxicity

Finding Sources
Finding Sources
Searching the Web

cannabis toxicity clinical features management 2024

Reading File
Reading File
Reading File
Reading File
Reading File
Excellent - I now have comprehensive content from four major textbooks. Here is the full structured answer:

Cannabis Toxicity


1. General Lethality

The acute toxicity of cannabis is very low. There are no reported cases of fatal cannabis poisoning in the human medical literature. Animal studies show the dose of THC required to kill 50% of rodents is extremely high compared to other drugs, and the lethal dose increases further up the phylogenetic tree - suggesting that a lethal dose in humans cannot be achieved by smoking or ingestion.
(Kaplan & Sadock's Comprehensive Textbook of Psychiatry)

2. Acute Toxicity - Clinical Features

From Smoking/Vaping (rapid onset, 2-4 hours duration)

FeatureDetail
Mood changesEuphoria, relaxation, or anxiety/panic
TachycardiaMost reliable physiologic sign
Conjunctival injectionConsistent finding
Impaired short-term memoryDose-dependent
Appetite stimulation"Munchies" - very common
Decreased intraocular pressureCan be therapeutic in glaucoma
Urinary retentionLess common
Decreased testosteroneWith chronic use

From Edibles (delayed onset up to 4 hours, duration 6-12+ hours)

Edibles carry higher risk of overdose because:
  • Users re-dose while waiting for effects to begin
  • Dose is difficult to estimate
  • Effects are unpredictable in naive or infrequent users
  • "Cannabis tourists" and children are especially vulnerable
Massive oral ingestion can cause: profound ataxia, vomiting, agitation, severe anxiety, CNS depression
(Rosen's Emergency Medicine)

3. Pediatric Toxicity

Children accidentally consuming edibles (increasingly common after legalization) may present with:
  • Hypothermia, ataxia, nystagmus, tremor
  • Tachycardia, injected conjunctiva, labile affect
  • Drowsiness, hypotonia, lethargy
  • Seizures (less common)
  • Coma and airway obstruction requiring intubation in large ingestions
Pediatric exposures have been rising significantly with cannabis legalization across multiple states.
(Rosen's Emergency Medicine)

4. Neuropsychiatric Toxicity

  • Severe anxiety and panic attacks (especially with high-THC products)
  • Acute psychosis - can occur even without prior psychiatric history
  • Worsening of pre-existing psychotic disorders
  • Cannabis hyperemesis syndrome (CHS): cyclic severe nausea, vomiting, abdominal pain in chronic heavy users - often relieved by hot showers
  • Cognitive impairment, especially with adolescent use
  • High-potency cannabis (more THC, less CBD) carries the greatest psychosis risk
(Harrison's Principles of Internal Medicine 22E, Stahl's Psychopharmacology)

5. Cardiovascular Toxicity

THC produces cardiovascular effects through three mechanisms:
  1. Combustion products - similar toxicity profile to cigarette smoke
  2. Direct sympathomimetic effects - acute heart rate increase of 20-100%, supine hypertension, systemic catecholamine release causing coronary constriction and platelet activation
  3. Indirect effects - extreme anxiety, hallucinations, psychosis
Resulting risks:
  • Myocardial infarction (especially in middle-aged adults with pre-existing disease)
  • Stroke, arrhythmias, sudden death
  • Increased myocardial oxygen demand with inadequate compensatory coronary blood flow
  • Orthostatic hypotension - risk in elderly patients
  • Case reports of serious cardiovascular events in young, heavy daily cannabis smokers
  • Hospital data (1990-2014) showed increased cardiac-related deaths after medical cannabis policy passage, especially in older men
(Murray & Nadel's Respiratory Medicine, Kaplan & Sadock's)

6. Pulmonary Toxicity

  • Cannabis smoke delivers more carboxyhemoglobin and inhaled tar per cigarette than tobacco smoke
  • Deep inhalation with breath-holding increases exposure
  • Deep inhalation at near-total lung capacity can cause barotrauma - pneumothorax and pneumomediastinum
  • Chronic symptoms: laryngitis, wheezing, chronic cough, sputum production
  • Pulmonary fungal infections in immunocompromised cannabis smokers (diabetes, leukemia, chronic steroid use)
  • EVALI (e-cigarette/vaping associated lung injury): Severe acute hypoxemic respiratory failure/ARDS with ground-glass opacities on CT (subpleural sparing), linked to vitamin E acetate in illicit THC vape pens - first described in 2019
  • Cannabis smoking has not been clearly linked to lung cancer, likely due to lower frequency of use compared to tobacco
(Murray & Nadel's Textbook of Respiratory Medicine)

7. Synthetic Cannabinoids ("Spice," "K2")

Synthetic cannabinoids are far more dangerous than natural cannabis:
GenerationExamplesFeatures
First-genJWH-018, HU-210Tachycardia, agitation, N/V, hallucinations, seizures
Second-genADB-PINACA, AB-FUBINACASevere agitation/aggression, CNS depression, seizures, brady- and tachycardia, hypo- and hypertension, ischemic stroke, cardiac toxicity
Brodifacoum contamination outbreak: Over 160 cases in Illinois alone presented with multi-site bleeding from synthetic cannabinoids contaminated with long-acting vitamin K antagonist rodenticide - 4 deaths reported.
(Rosen's Emergency Medicine)

8. Management

SituationManagement
Panic/anxiety reactionReassurance, calm environment, prevent injury
PsychosisBenzodiazepines first-line; haloperidol for severe agitation
Cannabis hyperemesis syndromeHigh-dose antiemetics; hot showers/baths (patient-discovered relief); capsaicin cream has evidence
Pediatric ingestionSupportive care; monitor airway closely; intubation if needed
Cardiovascular eventStandard ACS/arrhythmia management
EVALICorticosteroids; supportive care; follow CDC guidelines
Synthetic cannabinoid toxicityAggressive supportive care; benzodiazepines for seizures/agitation
Brodifacoum contaminationVitamin K supplementation, long-term monitoring

9. Special Populations at Highest Risk

  • Children - accidental edible ingestion
  • Cannabis-naive users and tourists - unfamiliar with edible dosing and delayed onset
  • Elderly - orthostatic hypotension, cardiovascular risk
  • Patients with cardiovascular disease - MI, arrhythmia risk
  • Immunocompromised - pulmonary fungal infections
  • Pregnant women - fetal neurodevelopmental effects, cognitive deficits in offspring
  • Adolescents - neurodevelopmental harm, higher risk of psychosis

Sources:
  • Harrison's Principles of Internal Medicine 22E (2025) - Acute & Chronic Toxicity
  • Rosen's Emergency Medicine - Clinical Features, Differential Diagnosis
  • Murray & Nadel's Textbook of Respiratory Medicine - Pulmonary & Cardiovascular Toxicity
  • Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Pharmacology of Cannabinoids

Unilateral finger swelling of one feet

Finding Sources
Finding Sources
Searching the Web

unilateral single toe swelling differential diagnosis causes

Finding Sources
Finding Sources
Reading File
Reading File
Loading Image
Finding Sources
Finding Sources
I now have comprehensive content to provide a thorough answer. Here is the full structured response:

Unilateral Toe (Digit) Swelling - Differential Diagnosis & Approach

(Note: You likely mean swelling of a single toe on one foot - the clinical term is dactylitis when the whole digit is involved, or monoarthritis when limited to one joint.)

Key Concept: The "Sausage Digit" (Dactylitis)

Dactylitis = diffuse swelling of an entire single toe (or finger), representing a combination of:
  • Flexor tenosynovitis
  • Soft tissue edema
  • Bone edema
  • Synovitis
The feet are affected more commonly than the hands. Dactylitis is highly specific for a spondyloarthropathy.
Dactylitis of the second toe with nail changes in psoriatic arthritis
Dactylitis of the second toe with associated nail changes - Rheumatology, 2-Volume Set (Elsevier)

Differential Diagnosis - Organized by Likelihood

1. GOUT (Podagra) - Most Common Cause

Classic: Acute painful swelling of the 1st metatarsophalangeal (MTP) joint of the big toe
Key features:
  • Involved in 70-90% of gout cases (the 1st MTP joint)
  • Flares often begin at night or early morning
  • Joint becomes warm, red, tender, and substantially swollen
  • Can mimic cellulitis (pseudocellulitis)
  • Flares self-resolve within 1-2 weeks without treatment
  • Triggered by: purine-rich food, alcohol, diuretics, dehydration, trauma
Harrison's Principles of Internal Medicine 22E (2025)

2. Psoriatic Arthritis (PsA) - Dactylitis

  • Dactylitis occurs in 30-40% of PsA patients
  • Most commonly involves 1-2 digits at a time
  • Feet affected more than hands
  • Associated with DIP joint involvement and nail changes (pitting, onycholysis)
  • Long-term non-inflammatory swelling with loss of mobility can persist after the flare resolves
  • Look for skin psoriasis plaques elsewhere
Rheumatology, 2-Volume Set (Elsevier 2022)

3. Other Spondyloarthropathies Causing Dactylitis

Dactylitis is "very specific for a spondyloarthropathy" and occurs in:
ConditionClues
Psoriatic arthritisSkin psoriasis, nail changes, DIP involvement
Reactive arthritis (Reiter's)Preceding GI/GU infection, urethritis, conjunctivitis, oral ulcers
Ankylosing spondylitisYoung male, back pain, sacroiliitis
IBD-associated arthritisCrohn's/ulcerative colitis
Firestein & Kelley's Textbook of Rheumatology

4. Septic Arthritis / Osteomyelitis

  • Bacterial infection of the joint or bone
  • Hot, swollen, exquisitely tender single joint
  • Fever, elevated WBC, raised CRP/ESR
  • Risk factors: diabetes, immunosuppression, penetrating injury, IV drug use
  • Medical emergency - requires urgent joint aspiration and antibiotics

5. Trauma / Fracture

  • History of injury (dropping object, stubbing toe)
  • Stress fractures (less severe, insidious onset)
  • Bruising may appear the next day
  • Confirm with X-ray

6. Ingrown Toenail (Onychocryptosis)

  • Nail edge grows into periungual skin
  • Redness, swelling, pain at the nail fold
  • Can become secondarily infected (paronychia)
  • Usually affects the great toe

7. Cellulitis / Soft Tissue Infection

  • Spreading erythema, warmth, swelling of the toe/foot
  • No joint effusion on examination
  • May follow a small wound, insect bite, or tinea pedis
  • Can co-exist with or be confused with gout

8. Calcium Pyrophosphate Deposition (CPPD / Pseudogout)

  • Similar presentation to gout but first MTP rarely involved
  • More commonly knee or wrist
  • Diagnosed by joint aspiration (rhomboid crystals vs. needle-shaped in gout)

9. Chronic Tophaceous Gout

  • Painless subcutaneous tophi (chalky deposits) in and around toe joints
  • Occurs after years of untreated hyperuricemia
  • Bony destruction and deformity on X-ray

Distinguishing Features at a Glance

FeatureGoutPsA DactylitisSeptic ArthritisTrauma
OnsetSudden, nocturnalGradualAcuteAfter injury
Joints1st MTP > ankle/kneeAny digit, DIPSingle jointAny
PainSevereModerateSevereAfter trauma
SkinNormalPsoriasis plaquesHot, redBruising
FeverLow-grade possibleAbsentHigh feverAbsent
NailsNormalPitting/onycholysisNormalNormal
Crystal aspirateUrate (needle)NegativeOrganismsNegative

Investigations to Order

  1. Serum uric acid - elevated in gout (note: can be normal during an acute flare)
  2. FBC, CRP, ESR - elevated in infection/inflammation
  3. X-ray foot - bony erosions, fractures, soft tissue swelling
  4. Joint aspiration (arthrocentesis) - gold standard; crystals under polarized light microscopy
  5. Ultrasound or MRI - if dactylitis suspected; shows tenosynovitis + synovitis extent
  6. HLA-B27 - if spondyloarthropathy suspected
  7. Skin examination - psoriasis plaques, nail changes
  8. Blood cultures - if septic arthritis suspected

Red Flags Requiring Urgent Assessment

  • High fever with hot swollen joint (septic arthritis - emergency)
  • Rapidly spreading redness up the leg (necrotizing fasciitis)
  • Diabetic foot with any wound/swelling
  • Crepitus on palpation (gas-forming organisms)

Sources:
  • Harrison's Principles of Internal Medicine 22E (2025) - Gout, Clinical Manifestations
  • Rheumatology, 2-Volume Set (Elsevier 2022) - Dactylitis in PsA
  • Firestein & Kelley's Textbook of Rheumatology - Spondyloarthropathy features
  • Miller's Review of Orthopaedics, 9th Ed. - Crystal deposition disease

Treatment

Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Excellent - comprehensive treatment data gathered. Here is the full treatment guide covering all major causes:

Treatment of Unilateral Toe Swelling - by Cause


1. GOUT (Podagra) Treatment

Acute Flare Management

Early initiation is key - treat as soon as possible and continue until the flare fully resolves (usually 6-10 days).
DrugDose/Notes
NSAIDs (first-line)Indomethacin is the classic choice; any NSAID effective. Avoid in renal impairment, peptic ulcer disease
ColchicineMust be given within 36 hours of onset to be effective. Relieves pain within 12 hours. SE: nausea, vomiting, diarrhea, myopathy with chronic use
CorticosteroidsIntra-articular injection preferred when only 1-2 joints are involved; systemic steroids for polyarticular involvement
Important: Patients already on urate-lowering therapy (ULT) should continue it uninterrupted during a flare. ULT can also be safely started during an acute flare as long as anti-inflammatory cover is continued for several months.
(Goldman-Cecil Medicine, Lippincott Pharmacology)

Colchicine - Mechanism

Colchicine binds tubulin, causing microtubule depolymerization. This disrupts neutrophil mobility and migration into the inflamed joint. It is specific for gout - relief of pain within 12 hours confirms the diagnosis.
(Lippincott Illustrated Reviews: Pharmacology)

Chronic Gout - Urate-Lowering Therapy (ULT)

Treat-to-target: Reduce serum uric acid to < 6.0 mg/dL (or < 5.0 mg/dL in advanced disease)
Indications for ULT:
  • ≥2 gout flares per year
  • Single flare with CKD stage ≥3 or serum urate ≥9 mg/dL
  • Tophi present
  • Kidney stones
DrugClassDetails
Allopurinol (first-line)Xanthine oxidase inhibitorStart ≤100 mg/day; escalate by 100 mg every 2-5 weeks; max 800 mg/day. Start 50 mg in CKD
Febuxostat (alternative)Xanthine oxidase inhibitor40-80 mg/day. 80 mg more effective than 300 mg allopurinol for target attainment. Use if allopurinol failed/intolerant. Note: one study showed higher all-cause mortality vs. allopurinol - caution in CV disease
ProbenecidUricosuricIncreases uric acid excretion. Second-line; avoid in renal stones
Important: Starting ULT causes rapid shifts in serum urate which can precipitate an acute flare. Cover with low-dose colchicine, NSAIDs, or corticosteroids for at least 6 months after initiating ULT.
(Goldman-Cecil Medicine, Goodman & Gilman's Pharmacology)

Lifestyle Modifications (ACR Recommendations)

AvoidLimitEncourage
Organ meatsBeef, pork, lamb, shellfishLow-fat dairy
High-fructose corn syrup drinksBeer and spiritsExercise and fitness
Alcohol overuseAdequate hydration
Weight loss if obese
Smoking cessation

2. Psoriatic Arthritis / Dactylitis Treatment

Step-Up Algorithm (EULAR/GRAPPA Guidelines)

Step 1 - First-line: NSAIDs + Physical Therapy
  • NSAIDs for peripheral arthritis and dactylitis
  • Corticosteroid injections (with caution)
Step 2 - csDMARDs (conventional synthetic):
  • Methotrexate - first-line; effective for skin, nails, arthritis. Monitor LFTs, blood counts, renal function. Folic acid 1 mg/day mandatory
  • Leflunomide - effective for skin and arthritis
  • Sulfasalazine - used for peripheral arthritis
Note: For enthesitis or spondylitis, skip straight to biologics - csDMARDs are not effective for these domains.
Step 3 - Targeted synthetic DMARD:
  • Apremilast (PDE4 inhibitor) - effective for dactylitis and arthritis. SE: weight loss (10%), depression (1%)
Step 4 - Biologic DMARDs:
DrugClassEffective for Dactylitis?
Infliximab, Adalimumab, Certolizumab, GolimumabTNF inhibitors (first-line biologics)Yes
UstekinumabIL-12/23 inhibitorYes (also effective for Crohn's)
Secukinumab, IxekizumabIL-17 inhibitorsYes - highest efficacy for skin; caution if IBD
Treat-to-target: Assessment every 3 months (minimum every 6 months) aiming for minimal disease activity or remission.
(Fitzpatrick's Dermatology, Rheumatology 2-Volume Set)

3. Septic Arthritis Treatment

This is a medical emergency - immediate action required.
InterventionDetail
IV antibioticsStart empirically based on Gram stain; narrow based on culture results
Joint drainageMandatory - daily needle aspiration or surgical washout
Rest and splintageAffected limb
Analgesia
Blood culturesBefore starting antibiotics
Empiric antibiotic choice:
  • Gram-positive cocci (most common - Staph aureus): IV flucloxacillin or vancomycin (if MRSA suspected)
  • Gram-negative rods: IV cephalosporin or piperacillin-tazobactam
  • Sexually active young adults: cover N. gonorrhoeae - IV ceftriaxone
  • Duration: typically 4-6 weeks total (IV then oral)
(Textbook of Family Medicine, Rosen's Emergency Medicine, Bailey & Love's Surgery)

4. Trauma / Fracture Treatment

SeverityManagement
Simple toe fractureBuddy-strapping to adjacent toe, stiff-soled shoe, ice, elevation, NSAIDs
Displaced/unstable fractureOrthopaedic review, possible K-wire fixation
Stress fractureRest, offloading, activity modification

5. Cellulitis / Soft Tissue Infection Treatment

SeverityTreatment
Mild (no systemic features)Oral antibiotics: flucloxacillin or amoxicillin-clavulanate; limb elevation
Severe / spreadingIV antibiotics; admit; mark margins to monitor progression
Diabetic footBroad-spectrum cover; vascular assessment; podiatry referral

6. Ingrown Toenail Treatment

StageTreatment
Mild (no infection)Cotton-wool wedging under nail, warm soaks, correct footwear
InfectedOral antibiotics + topical antiseptic
Recurrent/severePartial nail avulsion (wedge resection) under local anaesthetic; phenol ablation of nail matrix

Summary Treatment Ladder

Single hot swollen toe
        ↓
Is it septic arthritis? → YES → Admit, IV antibiotics + joint drainage
        ↓ NO
Is it gout? → YES → NSAIDs/colchicine/steroids (acute)
                      + ULT after flare (allopurinol)
        ↓ NO
Is it dactylitis (PsA)? → YES → NSAIDs → csDMARDs → Biologics
        ↓ NO
Trauma → Buddy strapping, rest, analgesia
Cellulitis → Antibiotics, elevation
Ingrown nail → Nail care, antibiotics if infected

Sources:
  • Goldman-Cecil Medicine - Gout treatment, treat-to-target
  • Lippincott Illustrated Reviews: Pharmacology - Colchicine, acute gout
  • Goodman & Gilman's Pharmacological Basis of Therapeutics - Febuxostat/allopurinol
  • Fitzpatrick's Dermatology, 2-Volume Set - PsA treatment algorithm (EULAR/GRAPPA)
  • Rosen's Emergency Medicine - Septic arthritis management
This is a shared conversation. Sign in to Orris to start your own chat.